However, p21 mutant pituitaries have significantly less mRNA of Myc and the cyclins Ccnb1, Ccnd1, Ccnd2 and Ccne1 than wildtype pituitaries. Interestingly, unlike the redundant role in cell cycle inhibition uncovered in p27/p57 double mutants, the pituitary of p21/p27 double mutants has a similar proliferation profile to p27 single mutants at the time points examined. Taken together, these studies demonstrate that unlike p27 or p57, p21 does not play a major role in control of progenitor proliferation in the developing pituitary. However, p21 may be required to maintain normal levels of cell cycle components.
Introduction
Pituitary gland development is reliant on the coordination of signaling pathways and molecular mechanisms that direct the regulated appearance of the six major endocrine cell types: corticotropes, thyrotropes, gonadotropes, somatotropes, lactotropes and melanotropes. The pituitary is induced from the oral ectoderm at embryonic day 9.5 (e9.5) in the mouse. It consists of a population of highly proliferative progenitors located in a structure known as Rathke's pouch (RP) (Ikeda and Yoshimoto, 1991) . Initially, RP cells contain SOX2, a marker of progenitor and stem cell populations ( Fauquier et al., 2008) .
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As development proceeds, cells exit the cell cycle, extinguish SOX2 and begin to express hormones. By e18.5, although a small population of SOX2 containing proliferative cells remains, the pituitary is equipped with all hormone cell types and is ready for secretory function (Fauquier et al., 2008; GarciaLavandeira et al., 2009 ). In the postnatal gland it is less clear what cell type is proliferating to expand the pituitary to adult proportions. However, there is evidence to indicate that the SOX2 expressing cells, which line the lumen that separates the anterior and intermediate lobes and are scattered throughout the anterior lobe, play a role in this process (Fauquier et al., 2008) . Alternatively, in the rat, mitosis of cells that have already differentiated to contain hormones has been described (Taniguchi et al., 2002 (Taniguchi et al., , 2001a (Taniguchi et al., ,b,c, 2000 . Regardless of cell type or timing of differentiation, it is clear that the highly orchestrated expansion of pituitary progenitors and their subsequent differentiation is reliant on tightly regulated fluctuations in components of the cell cycle.
Recent studies have shown that direct regulation of cell cycle molecules is the mechanism by which the cell fate choice of proliferation versus differentiation is modulated in the developing pituitary. PITX2, a transcription factor necessary for pituitary formation, participates in promoting proliferation by activating Ccnd2 transcription, a molecule needed to transition cycling cells from the G1 to the S phase of the cell cycle (Kioussi et al., 2002) . Furthermore, Notch signaling is essential for maintaining proliferative progenitors in RP (Monahan et al., 2009; Raetzman et al., 2004; Zhu et al., 2006) . Recent evidence shows that the Notch target HES1 is a transcriptional repressor essential for preventing cyclin dependent kinase inhibitor (CDKI) expression in pituitary progenitors, and that loss of Hes1 increases CDKI expression and subsequently depletes the progenitor pool (Monahan et al., 2009) .
Induction of CDKI expression has been shown to be the hallmark of differentiating tissues, which need to enter into a non-proliferative state before cell specification. In the pituitary, p21, p27 and p57, members of the CIP/KIP family of CDKIs, are found in RP cells. p57 expression is localized to non-cycling cells during stages of anterior lobe cell specification, likely serving as the critical mediator of progenitor cell cycle exit. Loss of p57 results in pituitary hyperplasia due to an increase in proliferating progenitors seen as early as e12.5. Conversely, overexpression of p57 results in pituitary hypoplasia, indicating that there are fewer proliferating progenitors (Bilodeau et al., 2009 ). p27 expression is detected in the pituitary starting at e12.5, an age when hormone cell types begin to emerge (Brinkmeier et al., 2007) . Loss of both p27 and p57 results in increased proliferation of pituitary progenitors at e14.5, suggesting that proper regulation of these molecules is needed to restrain progenitor expansion ( Bilodeau et al., 2009) . Although p21 is present in RP at e10.5 and its expression is strongly induced upon loss of Hes1, its role in pituitary development is unknown (Monahan et al., 2009) .
In addition to influencing development, CDKIs also play a part in maintaining adult tissue quiescence. Dysregulation of CDKIs has been shown to be prevalent in many types of tumors and cancers (Musat et al., 2004; Quereda and Malumbres, 2009) . Pituitary tumors are detected incidentally in 12% of the population (Buurman and Saeger, 2006) . The prevalence of clinically detected tumors is close to 1:1000 (Daly et al., 2006; Fernandez et al., 2010) . Although mutations in p21 are not common in pituitary tumors ( Burrow et al., 1981; Ezzat et al., 2004) , p21 expression is induced in GH producing human pituitary tumors, and this induction has been shown to be essential to limit pituitary tumor size in mice (Chesnokova et al., 2005 (Chesnokova et al., , 2008 . Interestingly, p21 is not expressed in null cell adenomas, which do not express hormone and generally grow larger than their hormone secreting counterparts (Neto et al., 2005) . p21 mutant mice exhibit impaired G1 checkpoint progression (Brugarolas et al., 2002; Deng et al., 1995) which leads to spontaneous tumor formation seen at approximately 16 months of age, however pituitary tumors have not been reported (MartinCaballero et al., 2001) . Unlike p21, p27 is commonly dysregulated in a variety of human cancers (Bamberger et al., 1999) . Loss of functional p27 has been identified as a rare cause of the disorder multiple endocrine neoplasia (MEN), which includes pituitary tumor formation, in both humans and rats (Pellegata et al., 2006; Georgitsi et al., 2007) . Loss of p27 in the mouse results in overall pituitary hyperplasia and intermediate lobe tumor formation ( Fero et al., 1996; Kiyokawa et al., 1996; Nakayama et al., 1996) .
Consistent with a two-hit model, pituitary tumor susceptibility appears to be increased when multiple cell cycle molecules are dysregulated. Mice lacking the retinoblastoma gene, Rb, form intermediate lobe pituitary tumors with increased incidence and shorter latency when either p21 or p27 is also lost (Brugarolas et al., 1998; Park et al., 1999) . This synergistic action may explain why loss of multiple CDKIs leads to increased tumor susceptibility. Loss of p18, another CDKI, in addition to loss of p21 or p27 again reveals decreased tumor latency indicating that expression of CDKIs is necessary to restrain tumor growth by either a synergistic or redundant manner (Franklin et al., 2000 (Franklin et al., , 1998 .
In addition to the role of p21 in cell cycle control, it has also been shown to play a role in cell death regulation. Thymocytes isolated from p21 mutant animals have been found to be hypersensitive to radiation induced programmed cell death via the p53 pathway (Fotedar et al., 1999) . Additionally, p21 overexpression has been shown to induce apoptosis in vitro in esophageal and cervical cancer cell lines (Kadowaki et al., 1999; Tsao et al., 1999) . In p53-dependent human hepatoma cell lines, overexpression of p21 results in an induction of Bax, a pro-apoptotic protein (Kang et al., 1999) . In addition to p21 misexpression, Hes1 mutant pituitaries have increased cell death in an area coincident with p21 expression, indicating that p21 may be mediating senescence-induced cell death in the pituitary as well (Monahan et al., 2009) . Recent evidence has shown that a wave of p21 expression is followed by induced cell death that is required for proper separation of the digits in the forelimb in the rodent (Vasey et al., 2010) . Together these studies suggest that p21 activation may be part of the mechanism regulating properly controlled cell death.
The prevalence of pituitary tumors in the population warrants investigations into what molecular mechanisms are needed to guard against excess proliferation in the embryo and the adult stem/progenitor cells. Studies have already shown the potential for CDKIs, specifically of the CIP/KIP family, to operate as tumor suppressors. Here we show that p21, unlike p27 and p57, is not needed to restrain progenitor cell expansion in the embryonic pituitary. However, by the third postnatal week, although there is no overall change in pituitary size, loss of p21 results in aberrant expression of specific cell cycle components.
Results
2.1. p21 expression is found in embryonic and postnatal pituitaries p21 is present in isolated cells in the pituitary throughout development as well as during postnatal life. At e10.5, a time when cells throughout RP are highly proliferative progenitors, p21 expression is located in cells concentrated at the juncture between RP and the oral ectoderm (OE) (Fig. 1A) . At e11.5, p21 is localized to scattered cells in the ventral aspect of RP as well as in the OE cells directly below RP (Fig. 1B) . By e12.5, the pituitary cells begin to form an outcropping in the ventral RP, forming the future anterior lobe. By this stage, p21 expression is present in a few cells within RP (Fig. 1C) . Similar sporadic detection of p21 at e14.5 ( Fig. 1D ) and e16.5 (Fig. 1E ) is also seen, mainly in cells within the anterior lobe. At postnatal day 21 (pd21), a time near the end of the postnatal proliferative phase, there are scattered p21 positive cells in the intermediate lobe (Fig. 1F , black arrowhead) and anterior lobe (Fig. 1G , black arrowhead).
2.2.
Loss of p21 subtly delays closure of Rathke's pouch but does not alter cell death During early pituitary development (e10.5-e11.5), p21 expression is restricted to a small population of cells at the border between RP progenitors and the underlying ectoderm. This limited expression, as well as its correlation to a small amount of cell death in the region ( Monahan et al., 2009 ), led us to speculate whether p21 may play a role in pouch separation from oral tissue. To determine if loss of p21 impairs timely separation of RP progenitors from the underlying oral ectoderm, pouch closure of wildtype and p21 mutant pituitaries was carefully examined. Embryos were somite staged to more precisely determine embryonic age, with somite stage 18 (ss18) denoting e11.5. At ss16, both wildtype and p21 mutant pituitaries appear to be connected to oral ectoderm, forming a structure that remains open to the oral cavity in the three wildtypes and three p21 mutants that were examined ( Fig. 2A and E) . By ss17, wildtype (Fig. 2B ) and p21 mutant pituitaries (Fig. 2F ) begin to close, although this closure is not complete in all embryos (two of five are closed in wildtype, one of five is closed in mutant). At ss18, the stereotypical e11.5, most of the wildtype (Fig. 2C ) pouches are no longer open (three of four are closed), forming a RP that is autonomous from the oral ectoderm. p21 mutant (Fig. 2G ) pituitaries at this stage are open in two of the four examined. By ss19, all three of the wildtype (Fig. 2D ) pouches examined are closed. p21 mutants (Fig. 2H ), on the other hand, still exhibit variable pouch closure (one of four are closed at this stage). Interestingly, by e12.5, both wildtype and p21 mutant pituitaries appear to have closed to the oral cavity.
Since the loss of p21 delays pouch separation to some extent, we hypothesized that p21 may promote cell death. In fact, a wave of p21 expression appears before induction of cell death seen in digit separation during embryonic development in the rodent (Vasey et al., 2010) . To investigate this hypothesis, we utilized TUNEL staining to detect areas of cell death in the developing pituitary. At e10.5, when the pituitary still remains open to the oral cavity, we can see small amounts of cell death in the junction between the RP and the oral ectoderm in both wildtype (Fig. 2I , arrowhead) and p21 mutants ( and in wildtype pituitaries at ss17 cell death is not found in RP but can be detected in the oral ectoderm directly beneath RP (Fig. 2J, arrowhead) . p21 mutant pituitaries at this somite stage show that when pouch closure is incomplete, cell death still occurs (Fig. 2N, arrowhead ). Yet, at ss18 and ss19 in both wildtype ( Fig. 2K and L) and p21 mutant pituitaries when pouch separation has occurred, changes in cell death are not detected ( Fig. 2O and P). By e12.5 pouch closure is complete in both animals and cell death is no longer apparent (data not shown). These data indicate that p21 is not mediating cell death in the developing pituitary.
p21 does not appear to regulate proliferation of progenitors early in development
In addition to its role in cell death, p21 is also a negative regulator of cell cycle progression. To determine if pituitary progenitors are actively proliferating in the presence and absence of p21, we performed immunohistochemistry utilizing established markers of proliferation including Ki67, which marks cells in all active phases of the cell cycle, and phosphohistone H3 (PH3), which marks cells transitioning into M and late G2 phase. At e10.5 in wildtype and p21 mutant pituitaries, the majority of RP progenitors are in some phase of the cell cycle as marked by Ki67 expression ( Fig. 3A and B) . PH3 staining in wildtype ( Fig. 3C ) and p21 mutants (Fig. 3D ) reveals that although most RP progenitors are in phases of active proliferation, only the cells lining the inner lumen of RP are actually completing the cell cycle and actively dividing. Ki67 and PH3 expression is mirrored in e11.5 pituitaries of both wildtype ( Fig. 3E and G) and p21 mutants ( Fig. 3F and H), with the majority of cells proliferating and lumen-restricted cells progressing through M phase. Additionally, cell count quantification of sections throughout the pituitary did not reveal significant Embryos were somite staged, sectioned sagittally and stained either for morphology with hematoxylin and eosin or for cell death with TUNEL (green) and counterstained with DAPI (blue). Somite stage 18 (ss18) is considered equivalent to e11.5. In the wildtype, the pouch typically remains open at ss16 (A) and ss17 (B) but is usually closed by ss18 (C) and ss19 (D). The p21 mutant also has an open pouch at ss16 (E) and ss17 (F) but unlike the wildtype continues to be open at ss18 (G) and ss19 (H). Cell death analysis reveals TUNEL positive cells in Rathke's pouch near oral ectoderm at e10.5 in the wildtype (I, arrowhead) and p21 mutant pituitary (M, arrowhead). By e11.5 (ss17-19) TUNEL positive cells are virtually absent from the pituitary but remain present in the underlying oral ectoderm (J-L, N-P, arrowheads). N P 3. Magnification = 200·. Scale bars = 50 lm. p = 0.119 for ss18 and 19.
alterations in PH3 positive cells in the p21 mutant when compared to the wildtype. Wildtype pituitaries have 19.00 ± 4.06% while p21 mutants have 20.47 ± 2.72% of PH3 positive cells (p = 0.375). At e12.5 the majority of RP progenitors in wildtype (Fig. 3I ) and p21 mutants (Fig. 3J) are still marked by Ki67 while the cells in the developing anterior lobe are exiting the cell cycle and entering into a quiescent state. This again is mirrored by PH3 expression with cells restricted to the luminal portion of RP, away from the developing anterior lobe, in both wildtype ( Fig. 3K ) and p21 mutants (Fig. 3L) . Additional examination of Cyclin E and phosphorylated Rb expression did not reveal any differences between wildtype and p21 mutants (Supplemental Fig. 1 ). These results indicate that p21 expression in the early pituitary gland may not play a major role in controlling proliferation. Furthermore, these data indicate that compensatory mechanisms could mask proliferation changes when p21 is lost.
2.4.
Loss of p21 in addition to p27 does not change proliferation at e16.5
To determine if another member of the CIP/KIP family of CDKIs, p27, has any overlapping functions with p21 during embryonic development, we examined pituitaries of mice lacking each inhibitor in isolation or as double mutants. Proliferation was analyzed in e16.5 pituitaries using the cell cycle markers PH3, Ki67 and BrdU incorporation. Wildtype pituitaries have PH3 positive cells scattered throughout the anterior lobe and intermediate lobe (Fig. 4A) . Furthermore, immunohistological analysis with Ki67 ( Fig. 4E) and BrdU (Fig. 4I) , which marks cells in the S-phase of the cell cycle, indicates that proliferating populations are scattered throughout the anterior lobe and developing intermediate lobe. Upon immunohistological examination, p21 mutant pituitaries appear to have an increase in PH3 positive cells (Fig. 4B) . Ki67 (Fig. 4F) and BrdU (Fig. 4J ) also appear to be increased in the p21 mutant pituitary. Additionally, cell counts on midsagittal sections confirm that there are significantly more PH3 positive cells when compared to wildtype pituitaries (Fig. 4M) . Upon more stringent examination, where PH3 positive cell quantification was conducted throughout the entire e16.5 pituitary and not only on midsagittal sections, there is no significant change compared to normalized wildtype pituitaries (Fig. 4N ). Further analysis of Ki67 and Myc mRNA, as well as cell cycle regulators Ccnd2 and Ccne1, demonstrates that in whole pituitaries at e16.5, there is no overall change in cycling cells (Fig. 5) . Taken together, this indicates that loss of p21 may alter proliferation in a localized area but total pituitary proliferation remains unchanged compared to wildtype. When compared to wildtype pituitaries, p27 mutant pituitaries, as expected, appear to have more proliferating cells in the anterior lobe as marked by PH3 (Fig. 4C) , Ki67 ( Fig. 4G ) and BrdU labeling (Fig. 4K ). Midsagittal quantification of PH3 positive cells as well as quantification throughout the pituitary show significantly more positive cells in the p27 mutant when compared to the normalized wildtype pituitaries ( Fig. 4M and N) , indicating that there is a significant increase in proliferating cells when p27 is lost. Like the p21 and p27 single mutant pituitaries, loss of both p21 and p27 results in an apparent increase in PH3 (Fig. 4D) , Ki67 (Fig. 4H) and BrdU ( Fig. 4L) immunoreactive cells assessed by histological examination compared to wildtype pituitaries. Indeed, an increase in proliferating cells is further supported by quantification of PH3 in midsagittal sections as well as sections throughout the pituitary compared to normalized wildtype pituitaries ( Fig. 4M and N) . However, there is not a significant difference between proliferation indices between p27 mutants and p21/ p27 double mutants.
2.5.
Morphology and proliferation does not appear altered in p21 mutants, compared to p27 and double mutants at postnatal day 21
Because expression analysis revealed there are cells expressing p21 during the period of postnatal proliferation, we examined the effect of loss of p21 during this stage, as well as its interaction with p27. At postnatal day 21 (pd21) a wildtype mouse pituitary contains a posterior lobe, intermediate lobe and anterior lobe and the histology of a p21 mutant pituitary ( Fig. 6B and F) is indistinguishable from the wildtype pituitary ( Fig. 6A and E) . The p27 mutant pituitary also contains a posterior lobe, intermediate lobe and anterior lobe (Fig. 6C) . However, we observe intermediate lobe hyperplasia with very densely packed cells and nodule-like formations already occurring at this early age (Fig. 6G) , a result similar to what is observed in p21/p27 double mutants ( Fig. 6D and H) . We then examined proliferation at pd21 using Ki67 as a marker. The wildtype pituitary contained scattered Ki67 positive cells throughout the intermediate lobe (Fig. 6I ) and anterior lobe (Fig. 6M) , as did the p21 mutant pituitary (Fig. 6J and N) . Interestingly, p27 mutant pituitaries revealed abnormal clustering of the Ki67 positive cells throughout the intermediate lobe (Fig. 6K) , with many positive cells in the anterior lobe (Fig. 6O) . Again, p21/p27 mutant pituitaries appeared similar to p27 mutants in the intermediate lobe (Fig. 6L ) and the anterior lobe (Fig. 6P) . Taken together, these data show that p27, but not p21, is critical for proper intermediate lobe size, cell density and proliferation during the postnatal period. Additionally, at this age, our data indicates that there appears to be no genetic interaction between p21 and p27.
2.6.
Alterations in cell cycle regulators occur postnatally with the loss of p21
To compare proliferation levels between the wildtype and p21 mutants at pd21, we performed quantitative RT-PCR for Fig. 4 -Proliferation is increased at e16.5 in p21, p27, and p21/p27 mutants. Coronal sections of e16.5 pituitaries were immunohistochemically stained for three different markers of proliferation: PH3, Ki67 and BrdU. In the wildtype (A), p21 mutant (B), p27 mutant (C) and p21/p27 mutant (D), PH3 positive cells indicating M phase are seen scattered throughout the intermediate and anterior lobes of the pituitary. Similarly, the general marker Ki67 is present in wildtype (E), p21 mutant (F), p27 mutant (G) and p21/p27 mutant (H) pituitaries. Additionally, BrdU marking S phase is present in wildtype (I), p21 mutant (J), p27 mutant (K) and p21/p27 mutant (L) pituitaries. PH3 positive cells were counted on midsagittal sections as well as sections throughout the whole pituitary for each of the genotypes. p21 (p = 0.05), p27 (p = 0.05) and p21/p27 (p = 0.02) mutant pituitaries all had significantly more PH3 positive cells in midsagittal sections when compared to wildtype pituitaries (M). However, when sections throughout the entire pituitary were counted, p27 (p = 0.0001) and p21/27 (p = 0.004) mutant pituitaries contained significantly more PH3 positive cells than wildtype pituitaries, but p21 (p = 0.25) mutants did not (N). N P 3 Magnification = 200·. Scale bar = 50 lm. a = p 6 0.05 compared to wildtype, b = p 6 0.05 compared to p21 mutant.
cell cycle components using whole pituitaries. In parallel to the immunohistochemistry, p21 mutant pituitaries had similar Ki67 mRNA levels to wildtypes. Interestingly, when we measured the levels of Myc, we found that, compared to wildtype pituitaries, p21 mutant pituitaries have significantly less Myc mRNA (Fig. 7A) .
Because we observed a decrease in Myc expression in p21 mutants, we investigated other cell cycle regulators to determine if any component of the cell cycle is misregulated. Cyclin B, D and E are all present in the pituitary and known to regulate the cell cycle either during development or tumor formation (Jordan et al., 2000; Qian et al., 1998; Roussel-Gervais et al., 2010; Turner et al., 2000) . We found that compared to the wildtype pituitary, the p21 mutants have significantly reduced mRNA levels of Ccnb1, Ccnd1, Ccnd2 and Ccne1 (Fig. 7B) .
To explore if there was a compensatory upregulation of CIP/KIP family members in the absence of p21, we compared the expression of p21 (Cdkn1a), p27 (Cdkn1b) and p57 (Cdkn1c) between the wildtype and p21 mutant. The mRNA expression of p21 is, as expected, not detectable in the p21 mutant pituitary. However, p27 and p57 are not significantly different from the wildtype in the p21 mutant pituitary (Fig. 7C ). In addition, p15, p18 and p19 are not affected by loss of p21 (data not shown). This indicates that the expression of the CDKIs examined do not rely on p21 expression. Taken together, these data demonstrate that p21 is required to achieve normal mRNA levels of several components of the cell cycle, however the overall number of cycling cells is likely unaffected by loss of p21.
Discussion
Properly timed expression of cell cycle inhibitors is needed to orchestrate developmental events that lead to a pituitary containing the appropriate number of endocrine cells. Studies have shown that CDKI expression is needed during embryonic pituitary development in order to control progenitor proliferation. In fact, loss of the CDKIs p27 and p57 results in excess proliferation in pituitary progenitors, as well in cells differentiated to express hormones ( Bilodeau et al., 2009 ). The third CIP/KIP family member, p21, is also expressed in the developing pituitary. p21 has a diverse set of described functions, including regulation of cell cycle arrest, inhibition of the G1 and G2 cell cycle phases in response to differentiation signals or genotoxic stress and modulation of cell death (Abbas and Dutta, 2009) . Previous work by our group has shown that in the pituitary, Notch signaling represses p21. In the absence of the Notch target gene Hes1, p21 expression is induced in a broader subset of cells, correlating with decreased progenitor cell proliferation and increased cell death (Monahan et al., 2009) . We now show that p21 alone is not an essential mediator of proliferation or cell death at early stages of pituitary development. However, during the postnatal period of cell expansion, proper expression of p21 does appear to play a role in cell cycle regulation as demonstrated by the reduction in mRNA levels of Myc as well as Ccnb1, Ccnd1 and Ccne1.
p21 can be a potent inhibitor of cell cycle progression. p21 represses the activity of the CyclinD/Cdk4 and CyclinE/Cdk2 complexes, which are needed for progression into S phase (Alt et al., 2002; Chen et al., 2002) . G1/S phase transition is a critical step in cycling progenitors, providing a checkpoint for cells to exit the cell cycle and begin differentiation. Additionally, the G1/S checkpoint serves as a mechanism for damaged cells to pause in the cell cycle, allowing for repair or apoptosis. p21 deficient cells that have been exposed to radiation or chemical carcinogens aberrantly progress in the cell cycle (Brugarolas et al., 2002) , highlighting the importance of p21 as a tumor suppressor. In addition to its role in G1/S phase, p21 can modulate the later G2/M transition by binding to and repressing Cyclin B activity (Smits et al., 2000) . Despite the role of p21 in several phases of the cell cycle, in the developing embryonic pituitary, proliferation is not dramatically altered in the absence of p21. Furthermore, p21 knockout mice have normal pituitary function, as indicated by their lack of endocrine related pathologies, which suggests that p21 is not required for controlling proliferation or differentiation in pituitary cells. A similar situation occurs in epithelial cells where loss of p21 does not alter cell cycle parameters, however p21 is essential for initiating the irreversible growth arrest known as senescence (Weinberg et al., 1999; Paramio et al., 2001) . Our studies do not, however, rule out that p21 acts in specific cohorts of cells that might have been missed by examining the pituitary as a whole. For example, like the pituitary, p21 is only expressed in a small number of cells in the pancreas (Chesnokova et al., 2009 ). However, a role for p21 in cell cycle inhibition is only observed when subsets of progenitors are separated and examined by flow cytometry (Miyatsuka et al., 2011) .
Proliferation of pituitary cells is not restricted to embryonic development. During the first weeks of postnatal life a second wave of proliferation expands the population of hormone cell types present in the pituitary (Taniguchi et al., 2002 (Taniguchi et al., , 2001b (Taniguchi et al., ,a,c, 2000 . Based on the fact that p21 is expressed in the pituitary at pd21, it is possible that p21 action may regulate this later stage of pituitary cell expansion. We find that although overall proliferation, as assessed by Ki67 immunohistochemistry and quantitative RT-PCR, is unchanged, there is evidence to suggest cell cycle components are reduced in the absence of p21. These data are consistent with the reduction of Cyclin D and Cyclin D/cdk4 complexes in both osteosarcoma and vascular smooth muscle cells depleted of p21 mRNA and in fibroblasts from p21 knockout mice (Cheng et al., 1999; LaBaer et al., 1997; Weiss et al., 2000) . These data suggest that in the right context, p21 may be necessary in the pituitary and other systems to support basal levels of the cell cycle machinery. In fact, in a model of a glial-derived brain tumor, p21 promoted tumor growth and loss of p21 resulted in a decrease in proliferation as marked by Ki67 (Liu et al., 2007) . Another way p21 can promote the cell cycle is by preventing Cyclin D/cdk4 export from the nucleus, which allows it to remain active (Alt et al., 2002) . Taken together, although high levels of p21 inhibit the kinase activity of CDKs and prevent cell cycle progression, low levels of p21 are necessary to maintain Cyclin levels and to permit formation of Cyclin D/cdk4 complexes allowing for cell cycle progression. This phenomenon may not be unique to p21 because a similar reduction in Cyclin mRNA levels was observed in 30 week old p27 mutant pituitaries, despite the increased organ size observed at this age (Oesterle et al., 2011) .
Although not usually detectable in adult pituitaries, p21 expression can be induced during tumor formation, where it plays an important function in restraining tumor growth. p21 expression is upregulated in Pttg/Rb mutant pituitaries (Chesnokova et al., 2005) . Loss of p21 in these Pttg/Rb mutant pituitaries results in increased tumor penetrance (Chesnokova et al., 2008) . Additionally, in a p18 mutant, additional loss of p21 results in an increased incidence of pituitary tumor formation (Franklin et al., 2000) . These studies indicate that p21 can be used to restrain proliferation in a context dependent manner and, when lost in addition to other key cell cycle regulators, allows for unrestrained growth and tumor formation. This led us to examine if p21 and p27 acted synergistically to induce proliferation. We find that unlike the cases described above, there is no interaction of p21 and p27, at least until pd21. Although this does not preclude the fact that a synergistic interaction may be observed at a later time point, it strongly suggests that these two CDKIs control different events in the pituitary.
In addition to its role in cell cycle regulation, p21 can also influence cell death. Expression of p21 is necessary to protect against apoptosis during differentiation, in response to growth factor withdrawal or ionizing radiation induced cell death (Fotedar et al., 1999; Jiang et al., 2000; Ozaki and Hanazawa, 2001 ). Yet, there is also evidence that shows that p21 can act as a pro-apoptotic protein. p21 overexpression has been shown to induce apoptosis in esophageal and cervical cell lines (Tsao et al., 1999; Kadowaki et al., 1999) . Furthermore, in p53 dependent hepatoma cell lines, p21 induces expression of Bax, a known pro-apoptotic protein ( Kang et al., 1999) . Highly regulated cell death occurs during development of many organs, including the brain and the pituitary. p21 expression is coincident with the location of cell death in the wildtype pituitary at e10.5 and is strikingly increased in the area of cell death observed in Hes1 mutants ( Monahan et al., 2009 ). This led us to hypothesize that p21 may mediate cell death during separation of the proliferating pituitary progenitors to create a RP distinct from the oral ectoderm. However, our studies show that loss of p21 does not result in changes in cell death, visualized by TUNEL. Nevertheless, in the absence of p21, RP fails to pinch off in a timely manner, with an open pouch phenotype appearing through ss19. Wildtype pituitaries on the other hand have separated from the oral ectoderm completely by this stage. This observation implies that specifically timed p21 expression promotes pouch closure, although the mechanism has yet to be determined.
With these current studies we show that changes in p21 at early stages of embryonic development may not influence pituitary progenitor proliferation or preserve cell survival. Expression at a narrow window of time indicates p21 may have a specific developmental action in the pituitary, but due to lack of changes at this stage in the mutant, direct consequences may not be readily apparent. It is likely that many cell cycle inhibitors are involved in coordinating the proliferation and differentiation of pituitary cells.
4.
Materials and methods
Mice
Cdkn1a (p21) mutant mice, with exons 2 and 3 replaced with pgk-neo cassette, were obtained from Dr. Paul S. Cooke's laboratory at the University of Illinois at Urbana-Champaign. These mice were originally generated by Dr. Tyler Jacks at the Massachusetts Institute of Technology ( Brugarolas et al., 1998) . Heterozygous males and females for the p21 mutant allele were mated to generate mixed genotype litters at e10.5-e12.5. Mice were genotyped using: p21 forward primer, 5 0 -ACT TTT GAT TGG CCT GAT GG-3 0 ; p21 reverse primer, 5 0 -TGA CGA AGT CAA AGT TCC ACC G-3 0 ; neo forward, 5 0 -GTC TTG TCG ATC AGG ATG ATC TG-3 0 ; neo reverse, 5 0 -CAA TAT CAC GGG TAG CCA ACG C-3 0 . Cdkn1b (p27) mutant mice, with pgk-neo cassette replacing the entire coding sequence, were obtained from the Jackson Laboratories and were generated by Dr. Matthew Fero at the Fred Hutchinson Center (Fero et al., 1996) . p21 homozygous mutant and p27 heterozygous mutant mice were first interbred for three generations to obtain consistent genetic background. Two separate breeding schemes were then undertaken to generate wildtype controls and p27 homozygous mutant mice, as well as p21 homozygous mutant and p21/p27 double mutant animals. The first were all significantly decreased in the p21 mutant pituitaries compared to wildtype (B). In the p21 mutant p21 mRNA was absent and there was no difference in p27 (p = 0.12) or p57 (p = 0.69) mRNA levels compared to wildtype (C). N = 7-8. * p 6 0.05.
scheme called for breeding of p21 homozygous mutant; p27 heterozygous mutant animals to generate litters of p21 mutant and p21/p27 mutant animals. The second scheme required breeding of p21 homozygous for the wildtype allele with p27 heterozygous mutant animals to generate litters of wildtype and p27 mutant mice. For genotyping p21 mutant mice with p27 mutant alleles the following primers were used: p21 wildtype forward primer, 5 0 -ACT TTT GAT TGG CCT GAT GG-3 0 ; p21 wildtype reverse primer, 5 0 -TGA CGA AGT CAA AGT TCC ACC G-3 0 . For the p27 genotyping the following primers were used to detect a wildtype band: p27 wildtype forward primer, 5 0 -GAT GGA CGC CAG ACA AGC-3 0 ; p27 wildtype reverse primer, 5 0 -CTC CTG CCA TTC GTA TCT GC-3 0 .
To detect a p27 mutant band the following primers were used: forward, 5 0 -GGC CAT TTT CCA TCT CTG AA-3 0 ; reverse 5 0 -CAA TAT CAC GGG TAG CCA ACG C-3 0 . The University of Illinois IACUC approved all procedures involving mice. For bromodeoxyuridine (BrdU) studies, mice were injected with 0.1 mg/g body weight BrdU intraperitoneally 30 min prior to sacrifice.
Sample collection
Embryos were collected and prepared for either immunohistochemistry or RNA extraction. For immunohistochemistry, the embryos were fixed in 3.8% formaldehyde solution (Fisher) in phosphate buffered saline (PBS) (Fisher), dehydrated through a graded series of ethanol and methyl salicylate and embedded in paraffin. Sections measuring 6 lm thick were then affixed to positively charged slides. For RNA extraction, e16.5 pituitaries were removed and placed in a lysis solution. Samples were then homogenized and RNA was extracted following the protocol outlined in the Ambion RNAqueousÒ Micro Kit (#1931). cDNA was created utilizing the New England BioLabs ProtoScript M-MuLV First Strand cDNA Synthesis Kit (#E6300L).
Pituitaries were removed from postnatal day 21 (pd21) mice and were prepared for either immunohistochemistry or RNA extraction. For immunohistochemistry, the pituitaries were fixed in 3.8% formaldehyde on ice for 1 h, rinsed with PBS, added to 30% sucrose at 4°C overnight, then snap frozen in OCT. The pituitaries were then sectioned with a cryostat (Leica), and the sections were adhered to charged slides. For RNA extraction, the pituitaries were snap frozen in microfuge tubes submerged in a dry ice/ethanol slurry. Prior to RNA extraction, cold RNAlater (Ambion, AM7021) was added to the tubes then incubated overnight at À20°C. The RNA extraction and cDNA synthesis were done in the same manner as for the embryo samples.
Immunohistochemistry
Embryo sections affixed to slides were deparaffinized in xylene, rehydrated in decreasing concentrations of ethanol and washed in PBS. Frozen pd21 pituitary slides were thawed at room temperature for 5 min, fixed in 3.8% formaldehyde for 10 min and rinsed with PBS. Slides were subjected to antigen retrieval using 0.01 M Citrate buffer, pH 6.0, for 10 min (paraffin) or 5 min of hot, non-boiling 0.01 M citrate buffer, pH 6.0 (frozen). All slides were blocked for 10-60 min using 5% Normal Donkey Serum (NDS, Jackson Immunoresearch) in an immunohistochemistry blocking solution (IHC block) containing 5% BSA, 0.1% Triton X-100 and PBS. Primary antibodies were diluted in IHC blocking solution at various dilutions: mouse anti-p21 (#556431 BD-Pharmingen) 1:500; rabbit antiPhosphohistone H3 (Ser 10, #06-570 Upstate Cell Signaling Solutions) 1:300; mouse anti-BrdU (#555627 BD Pharmingen) 1:50; rat anti-Ki67 (DAKO) 1:100; rabbit anti-CyclinE (ab52189 AbCam) 1:500; rabbit anti-phospho-Rb (Ser807/811, Cell Signaling Technology, #9308) 1:500. Donkey-derived mouse and rabbit secondary antibodies conjugated to biotin (Jackson Immunoresearch) were diluted to 1:200 and incubated with sections for 1 h followed by incubation with Streptavidin conjugated to cy3 fluorophore (Jackson Immunoresearch), for 1 h. Ki67 was detected with a secondary rat antibody conjugated to the fluorophore FITC or cy3. p21 was detected in e16.5 and pd21 tissue with a Vectastain kit (Vector Laboratories) diluted in PBS followed by Sigma Fast 3,3-diaminobenzidine tablets (Sigma) and counterstained with methyl green. Cell death was assessed by TUNEL as previously described (Raetzman et al., 2007) . All immunofluorescent slides were counterstained with 4 0 ,6-diamidino-2-phenylindole dihydrochloride (DAPI, Sigma 28718-90-3) at 1:1000 (Stock 1 mg/ml) and mounted using aqueous fluorescence mounting media. Samples were then visualized at 100·, 200· or 400·.
4.4.
Cell count analysis-phosphohistone H3
Midsagittal cell counts
Slides containing midsagittal sections from e11.5 WT and p21 mutant and e16.5 WT, p21 mutant, p27 mutant and p21/ p27 double mutant embryos were stained with PH3 and imaged as previously described. Images were taken at 200· magnification. For each genotype tested there was an n P 3 with at least two sections from each animal tested. All cells positive for PH3 were counted and a DAPI counterstaining was utilized to obtain an overall cell count for the whole 6-lm thick pituitary section. The proportion of immunoreactive cells was compared to the total number of DAPI positive cells contained within RP. A percentage of positive cells per pituitary section was determined using NIH Image J software, then statistically analyzed with a two tailed T-Test.
Total pituitary cell counts
To quantify proliferation throughout the developing pituitary at e16.5, immunohistochemistry was performed on every 4-5th slide through a sectioned pituitary. Slides containing sections from e16.5 WT, p21 mutant, p27 mutant and p21/ p27 double mutant embryos were stained with PH3 and imaged as described above. Images were taken at 200· magnification. For each genotype tested there were at least five embryos analyzed with five slides affixed with two sections for each animal tested. All cells positive for PH3 were counted and total pituitary section area was visualized by DAPI counterstaining of whole 6-lm thick pituitary section. The proportion of immunoreactive cells was compared to the area of RP as determined by tracing analysis on NIH Image J software. The number of positive cells per micron 2 area of pituitary per section was determined with total counts throughout all pituitary sections being added to provide a proliferation index for each animal tested. To determine statistical significance, ANOVA was performed using Stat Plus. A two tailed T-Test was then used to determine statistical significance between groups.
Quantitative RT-PCR
The following primer sequences and annealing temperatures were used during quantitative real time PCR: Gapdh forward primer 5 for each genotype and run on the Bio-Rad iQ5 Multicolor RealTime PCR Detection System Machine. Data was collected utilizing the Bio-Rad iQ5 Optical System Software Version 2.0 and analyzed in Microsoft Excel. The analysis was carried out using the change in cycle threshold value method as described by Goldberg et al. (2011) . A 2 tailed T-Test, conducted in Microsoft Excel, was utilized to determine statistical significance.
Somite staging
Somite number was determined by counting the appearance of somites behind the hind limb bud and to the tail of each animal at e11.5. Previous groups have characterized the e11.5 developmental stage as an embryo containing 18 somites past the hind limb bud (Karl and Capel, 1998) . Statistical significance was queried with a two tailed Fisher's exact test conducted in Graphpad Prism. All somite stages, and ss18 and 19 grouped, were compared between wildtype and p21 mutants.
